Vaxcyte Announces Pricing of $600 Million Public Offering
26 oct. 2022 00h20 HE
|
Vaxcyte, Inc.
SAN CARLOS, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
24 oct. 2022 16h01 HE
|
Vaxcyte, Inc.
SAN CARLOS, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...
Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64
24 oct. 2022 06h30 HE
|
Vaxcyte, Inc.
-- In the Study, VAX-24 Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20™ (PCV20) at All Doses Studied -- -- All 24 Serotypes of VAX-24 at Conventional 2.2mcg PCV Dose Met or...
Vaxcyte to Host Webcast and Conference Call to Discuss Topline Results from the Phase 1/2 Proof-of-Concept Study of VAX-24 Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults
23 oct. 2022 17h00 HE
|
Vaxcyte, Inc.
SAN CARLOS, Calif., Oct. 23, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...
Vaxcyte Expands Executive Leadership Team with Key Appointments
11 oct. 2022 16h05 HE
|
Vaxcyte, Inc.
-- Vaxcyte has Appointed Mark Wiggins, M.B.A. as Chief Business Officer and Jakub Simon M.D., M.S. as Chief Medical Officer as the Company Prepares to Enter Next Phase of Growth -- SAN CARLOS,...
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older
06 sept. 2022 16h04 HE
|
Vaxcyte, Inc.
-- Company Expects to Announce Topline Data from Study in Adults 65 Years and Older in the First Half of 2023 -- -- Vaxcyte Remains on Track to Announce Topline Data from the Phase 1 and Phase 2...
Vaxcyte Reports Second Quarter 2022 Financial Results and Provides Business Update
08 août 2022 16h15 HE
|
Vaxcyte, Inc.
-- Completed Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults -- -- Announcement of Topline Results...
Vaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs
04 août 2022 08h30 HE
|
Vaxcyte, Inc.
-- Company Receives FDA Fast Track Designation for VAX-24 in Adults -- -- Vaxcyte Completes Successful Pre-IND Meeting with FDA Regarding VAX-24 Pediatric Program, Supporting Path to Proceed Directly...
Vaxcyte Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults
12 juil. 2022 16h05 HE
|
Vaxcyte, Inc.
-- Company Expects to Announce Topline Results from the Phase 1 and Phase 2 Portions of the Proof-of-Concept Study in October or November 2022 -- -- Vaxcyte Also Dosed First Participants in Separate...
Vaxcyte to Present at the Jefferies Healthcare Conference
02 juin 2022 16h05 HE
|
Vaxcyte, Inc.
SAN CARLOS, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...